Evidence map›Paper›PMID 42147376›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2026

Current trends and future directions of artificial intelligence in lung cancer diagnosis.

Weilong Hu, Gang Wang, Li Ren, Jie Hu, Xiaopeng Wu, Weihua Zhuang, Yongchao Yao, Chengdi Wang, Feng Ye, Wenjun Mao and 1 more

Abstract read
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Weilong Hu *Department of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.
Gang Wang *Department of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.
Li Ren *Department of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.
Jie HuDepartment of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.
Xiaopeng WuDepartment of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.
Weihua ZhuangDepartment of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.
Yongchao YaoDepartment of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.
Chengdi WangDepartment of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610212, China.
Feng YeDepartment of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.
Wenjun MaoDepartment of Thoracic Surgery, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China.
Wenchuang HuDepartment of Laboratory Medicine, Precision Medicine Translational Research Center (PMTRC), West China Hospital, Sichuan University, Chengdu 610212, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the most lethal malignancy worldwide, largely due to its late detection after its progression to advanced stages. Over the last decade, artificial intelligence (AI) applications have shown significant potential in transforming lung cancer diagnostics by improving the speed, accuracy, and personalization of early detection strategies. This review provides a comprehensive overview of current AI application landscape in early lung cancer diagnosis, encompassing medical imaging, histopathology, liquid biopsy, natural language processing of electronic health records, and genomic profiling. We explain how machine learning, deep learning, and transformer-based models are employed in lung cancer diagnosis, and summarize recent cutting-edge advances, including multimodal AI platforms and Food and Drug Administration (FDA)-approved computer-aided diagnosis/detection (CAD) systems. Furthermore, we evaluate the challenges that impede clinical translation, including data heterogeneity, interpretability, and privacy, and present prospective directions such as federated learning and multi-omics integration. Through a comprehensive analysis of the dynamic evolution of AI applications in oncology, we aim to inform researchers, clinicians, and policymakers about its diagnostic potential and translational relevance in clinical practice.

Indexed as

artificial intelligencedeep learningearly diagnosislung cancerMachine learning

Identifiers

PMID42147376
PMCPMC13171413

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.